SYNOPSYS INC false 0000883241 0000883241 2024-12-04 2024-12-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): December 4, 2024

 

 

SYNOPSYS, INC.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   000-19807   56-1546236

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

675 Almanor Ave.

Sunnyvale, California 94085

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (650) 584-5000

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock (par value of $0.01 per share)   SNPS   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 2.02

Results of Operations and Financial Condition.

On December 4, 2024, Synopsys, Inc. (“Synopsys”, “we”, “our”, or “us”) issued a press release announcing the financial results of its fourth fiscal quarter and fiscal year ended October 31, 2024. A copy of the press release is furnished and attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto and incorporated by reference herein, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission by Synopsys whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

  

Exhibit Title

99.1    Press release dated December 4, 2024 containing Synopsys, Inc.’s results of operations for its fourth fiscal quarter and fiscal year ended October 31, 2024.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

    SYNOPSYS, INC.
Dated: December 4, 2024     By:  

/s/ John F. Runkel, Jr.

      John F. Runkel, Jr.
      General Counsel and Corporate Secretary

EXHIBIT 99.1

PRESS RELEASE

INVESTOR CONTACT:

Trey Campbell

Synopsys, Inc.

650-584-4289

Synopsys-ir@synopsys.com

EDITORIAL CONTACT:

Cara Walker

Synopsys, Inc.

650-584-5000

corp-pr@synopsys.com

Synopsys Posts Financial Results for Fourth Quarter and Fiscal Year 2024

Results Summary1

 

   

Record quarterly revenue of $1.636 billion, up approximately 11% year over year (YoY), exceeding the mid-point of guidance.

 

   

Quarterly GAAP earnings per diluted share (EPS) of $1.79; non-GAAP EPS of $3.40, up approximately 13% YoY, exceeding guidance.

 

   

Achieved record full-year 2024 revenue of $6.127 billion, up approximately 15% YoY, while improving non-GAAP operating margin and delivering approximately 25% non-GAAP EPS growth.

 

   

Expecting to deliver double digit revenue growth in 2025 while preparing for Ansys acquisition close, which remains on-track for the first half of 2025.

SUNNYVALE, Calif. Dec. 4, 2024Synopsys, Inc. (Nasdaq: SNPS) today reported results for its fourth quarter and fiscal year 2024. Revenue for the fourth quarter of fiscal year 2024 was $1.636 billion, compared to $1.467 billion for the fourth quarter of fiscal year 2023. Revenue for fiscal year 2024 was $6.127 billion, an increase of approximately 15% from $5.318 billion in fiscal year 2023.

 

1 

On September 30, 2024, Synopsys completed the sale of its Software Integrity business. Synopsys’ Software Integrity business has been presented as a discontinued operation in the consolidated financial statements for all periods presented herein and all financial results and targets are presented herein on a continuing operations basis unless otherwise noted.

 

1


“The fourth quarter was a strong finish to a transformational year for Synopsys. We achieved record financial results while doubling down on our strategy with the sale of our Software Integrity business and the pending acquisition of Ansys,” said Sassine Ghazi, president and CEO of Synopsys. “Looking ahead, the AI-driven reinvention of compute is accelerating the pace, scale and complexity of technology R&D, which expands our opportunity to solve engineering challenges from silicon to systems.”

“Continued strong execution drove excellent Q4 results, which exceeded the midpoint of our guidance targets and capped a year of 15% revenue growth for the company,” said Shelagh Glaser, CFO of Synopsys. “The combination of our execution focus, operating discipline, and the critical nature of our industry-leading technology positions us well for the future. In 2025, we expect to deliver double-digit revenue growth grounded in pragmatism given continued macro uncertainties and the impact of our fiscal year calendar change.”

Synopsys’ previously announced acquisition of Ansys is expected to close in the first half of 2025, subject to the receipt of required regulatory approvals and other customary closing conditions. This week marked the expiration of the Hart-Scott-Rodino (HSR) Act waiting period, and Synopsys is working cooperatively with Federal Trade Commission (FTC) staff to conclude the investigation and the staff’s review of Synopsys’ proposed remedies.

Continuing Operations

On September 30, 2024, Synopsys completed the sale of its Software Integrity business. Unless otherwise noted, Synopsys’ Software Integrity business has been presented as a discontinued operation in the Synopsys’ consolidated financial statements for all periods presented herein and all financial results and targets are presented herein on a continuing operations basis.

GAAP Results

On a U.S. generally accepted accounting principles (GAAP) basis, net income for the fourth quarter of fiscal year 2024 was $279.3 million, or $1.79 per diluted share, compared to $346.1 million, or $2.23 per diluted share, for the fourth quarter of fiscal year 2023. GAAP net income for fiscal year 2024 was $1.442 billion, or $9.25 per diluted share, compared to $1.227 billion, or $7.91 per diluted share, for fiscal year 2023.

 

2


Non-GAAP Results

On a non-GAAP basis, net income for the fourth quarter of fiscal year 2024 was $529.9 million, or $3.40 per diluted share, compared to non-GAAP net income of $464.1 million, or $3.00 per diluted share, for the fourth quarter of fiscal year 2023. Non-GAAP net income for fiscal year 2024 was $2.058 billion, or $13.20 per diluted share, compared to non-GAAP net income of $1.636 billion, or $10.54 per diluted share, for fiscal year 2023.

For a reconciliation of net income, earnings per diluted share and other measures on a GAAP and non-GAAP basis, see “GAAP to Non-GAAP Reconciliation” in the accompanying tables below.

Business Segments

Synopsys reports revenue and operating income in two segments: (1) Design Automation, which includes our advanced silicon design, verification products and services, system integration products and services, digital, custom and field programmable gate array IC design software, verification software and hardware products, manufacturing software products and other and (2) Design IP, which includes our interface, foundation, security, and embedded processor IP, IP subsystems, and IP implementation services.

Financial Targets

Synopsys also provided its consolidated financial targets for the first quarter and full fiscal year 2025. These targets reflect a change in Synopsys’ fiscal year from a 52/53-week period ending on the Saturday nearest to October 31 of each year to October 31 of each year. As a result of this change, there will be ten fewer days in the first half of fiscal year 2025 and two extra days in the second half of fiscal year 2025, which results in eight fewer days in the aggregate in Synopsys’ fiscal year 2025 as compared to its fiscal year 2024. These targets also assume no further changes to export control restrictions or the current U.S. government “Entity List” restrictions. These targets constitute forward-looking statements and are based on current expectations. For a discussion of factors that could cause actual results to differ materially from these targets, see “Forward-Looking Statements” below.

 

3


First Quarter and Full Fiscal Year 2025 Financial Targets (1)

(in millions except per share amounts)

 

     Range for Three Months Ending     Range for Fiscal Year Ending  
     January 31, 2025     October 31, 2025  
     Low     High     Low     High  

Revenue

   $  1,435     $  1,465     $  6,745     $  6,805  

GAAP Expenses

   $ 1,142     $ 1,162     $ 4,926     $ 4,983  

Non-GAAP Expenses

   $ 945     $ 955     $ 4,045     $ 4,085  

Non-GAAP Interest and Other Income (Expense), net

   $ 20     $ 22     $ 94     $ 98  

Non-GAAP Tax Rate

     16     16     16     16

Outstanding Shares (fully diluted)

     156       158       157       159  

GAAP EPS

   $ 1.81     $ 1.95     $ 10.42     $ 10.63  

Non-GAAP EPS

   $ 2.77     $ 2.82     $ 14.88     $ 14.96  

Operating Cash Flow

         ~ $1,800  

Free Cash Flow(2)

         ~ $1,600  

Capital Expenditures

         ~ $170  

 

(1)

Synopsys’ first quarter of fiscal year 2025 will end on January 31, 2025 and its fiscal year 2025 will end on October 31, 2025.

(2)

Free cash flow is calculated as cash provided from operating activities less capital expenditures.

For a reconciliation of Synopsys’ first quarter and fiscal year 2025 targets, including expenses, earnings per diluted share and other measures on a GAAP and non-GAAP basis and a discussion of the financial targets that we are not able to reconcile without unreasonable efforts, see “GAAP to Non-GAAP Reconciliation” in the accompanying tables below.

Earnings Call Open to Investors

Synopsys will hold a conference call for financial analysts and investors today at 2:00 p.m. Pacific Time. A live webcast of the call will be available on Synopsys’ corporate website at www.investor.synopsys.com. Synopsys uses its website as a tool to disclose important information about Synopsys and comply with its disclosure obligations under Regulation Fair Disclosure. A webcast replay will also be available on the corporate website from approximately 5:30 p.m. Pacific Time today through the time Synopsys announces its results for the first quarter of fiscal year 2025 in February 2025.

Effectiveness of Information

The targets included in this press release, the statements made during the earnings conference call, the information contained in the financial supplement and the corporate overview presentation, each of which are available on Synopsys’ corporate website at www.synopsys.com (collectively, the “Earnings Materials”), represent Synopsys’ expectations and beliefs as of December 4, 2024. Although these Earnings Materials will remain available on Synopsys’ website through the date of the earnings call for the first quarter of fiscal year 2025, their continued availability through such date does not mean that Synopsys is reaffirming or confirming their continued validity. Synopsys undertakes no duty and does not intend to update any forward-looking statement, whether as a result of new information or future events, or otherwise update, the targets given in this press release unless required by law.

 

4


Availability of Final Financial Statements

Synopsys will include final financial statements for the fiscal year 2024 in its annual report on Form 10-K to be filed on or before January 2, 2025.

About Synopsys

Catalyzing the era of pervasive intelligence, Synopsys, Inc. (Nasdaq: SNPS) delivers trusted and comprehensive silicon to systems design solutions, from electronic design automation to silicon IP and system verification and validation. We partner closely with semiconductor and systems customers across a wide range of industries to maximize their R&D capability and productivity, powering innovation today that ignites the ingenuity of tomorrow. Learn more at www.synopsys.com.

Reconciliation of Fourth Quarter and Fiscal Year 2024 Results

The following tables reconcile the specific items excluded from GAAP in the calculation of non-GAAP net income, earnings per diluted share, and tax rate for the periods indicated below.

GAAP to Non-GAAP Reconciliation of Fourth Quarter and Fiscal Year 2024 Results(1)

(unaudited and in thousands, except per share amounts)

 

     Three Months Ended      Twelve Months Ended  
     October 31,      October 31,  
     2024      2023      2024      2023  

GAAP net income from continuing operations attributed to Synopsys

   $ 279,281      $ 346,051      $ 1,441,710      $ 1,227,045  

Adjustments:

           

Amortization of acquired intangible assets

     54,258        14,886        104,220        50,477  

Stock-based compensation

     165,116        128,286        656,632        511,730  

Acquisition/divestiture related items

     62,428        4,016        172,638        13,831  

Restructuring charges

     —         (1,348      —         53,091  

Gain on sale of strategic investments

     —         —         (55,077      —   

Tax settlement

     —         —         —         (23,752

Tax adjustments

     (31,158      (27,753      (262,322      (196,471
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP net income from continuing operations attributed to Synopsys

   $  529,925      $  464,138      $  2,057,801      $  1,635,951  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

5


     Three Months Ended      Twelve Months Ended  
     October 31,      October 31,  
     2024      2023      2024      2023  

GAAP net income from continuing operations per diluted share attributed to Synopsys

   $ 1.79      $ 2.23      $ 9.25      $ 7.91  

Adjustments:

           

Amortization of acquired intangible assets

     0.35        0.10        0.67        0.33  

Stock-based compensation

     1.06        0.83        4.21        3.30  

Acquisition/divestiture related items

     0.40        0.03        1.11        0.09  

Restructuring charges

     —         (0.01      —         0.34  

Gain on sale of strategic investments

     —         —         (0.35      —   

Tax settlement

     —         —         —         (0.15

Tax adjustments

     (0.20      (0.18      (1.69      (1.28
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP net income from continuing operations per diluted share attributed to Synopsys

   $ 3.40      $ 3.00      $ 13.20      $ 10.54  
  

 

 

    

 

 

    

 

 

    

 

 

 

Shares used in computing net income per diluted share amounts:

     155,991        154,845        155,944        155,195  

 

(1)

Synopsys’ fourth quarter of fiscal year 2024 and 2023 ended on November 2, 2024 and October 28, 2023, respectively. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter.

GAAP to Non-GAAP Tax Rate Reconciliation (1)(2)

(unaudited)

 

     Twelve Months Ended  
     October 31, 2024  

GAAP effective tax rate

     6.6

Stock-based compensation

     2.9

Income tax adjustments (3)

     5.5
  

 

 

 

Non-GAAP effective tax rate

     15.0
  

 

 

 

 

(1)

Synopsys’ fiscal year 2024 ended on November 2, 2024. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter.

 

(2)

Presented on a continuing operations basis.

 

(3)

The adjustments are primarily related to the differences in the tax rate effect of certain deductions, such as the deduction for foreign-derived intangible income and credits.

 

6


GAAP to Non-GAAP Reconciliation of 2025 Targets

The following tables reconcile the specific items excluded from GAAP in the calculation of non-GAAP targets for the periods indicated below.

GAAP to Non-GAAP Reconciliation of First Quarter Fiscal Year 2025 Targets

(in thousands, except per share amounts)

 

     Range for Three Months Ending  
     January 31, 2025  
     Low      High  

Target GAAP expenses

   $  1,142,000      $  1,162,000  

Adjustments:

     

Amortization of acquired intangible assets

     (12,000      (15,000

Stock-based compensation

     (185,000      (192,000
  

 

 

    

 

 

 

Target non-GAAP expenses

   $ 945,000      $ 955,000  
  

 

 

    

 

 

 

 

     Range for Three Months Ending  
     January 31, 2025  
     Low      High  

Target GAAP earnings per diluted share attributed to Synopsys

   $ 1.81      $ 1.95  

Adjustments:

     

Amortization of acquired intangible assets

     0.10        0.08  

Stock-based compensation

     1.22        1.18  

Acquisition/divestiture related items (1)

     0.08        0.06  

Tax adjustments

     (0.44      (0.45
  

 

 

    

 

 

 

Target non-GAAP earnings per diluted share attributed to Synopsys

   $ 2.77      $ 2.82  
  

 

 

    

 

 

 

Shares used in non-GAAP calculation (midpoint of target range)

     157,000        157,000  

 

7


GAAP to Non-GAAP Reconciliation of Full Fiscal Year 2025 Targets

(in thousands, except per share amounts)

 

     Range for Fiscal Year Ending  
     October 31, 2025  
     Low      High  

Target GAAP expenses

   $  4,926,000      $  4,983,000  

Adjustments:

     

Amortization of acquired intangible assets

     (46,000      (51,000

Stock-based compensation

     (835,000      (847,000
  

 

 

    

 

 

 

Target non-GAAP expenses

   $ 4,045,000      $ 4,085,000  
  

 

 

    

 

 

 

 

     Range for Fiscal Year Ending  
     October 31, 2025  
     Low      High  

Target GAAP earnings per diluted share attributed to Synopsys

   $ 10.42      $ 10.63  

Adjustments:

     

Amortization of acquired intangible assets

     0.32        0.29  

Stock-based compensation

     5.36        5.28  

Acquisition/divestiture related items (1)

     0.29        0.26  

Tax adjustments

     (1.51      (1.50
  

 

 

    

 

 

 

Target non-GAAP earnings per diluted share attributed to Synopsys

   $ 14.88      $ 14.96  
  

 

 

    

 

 

 

Shares used in non-GAAP calculation (midpoint of target range)

     158,000        158,000  

 

(1)

Adjustments reflect certain contractually obligated financing fees and related amortization expenses, and do not fully reflect all potential adjustments for future periods for the reasons set forth in “GAAP to Non-GAAP Reconciliation” below.

Forward-Looking Statements

This press release and the investor conference call contain forward-looking statements, including, but not limited to, statements regarding short-term and long-term financial targets, expectations and objectives including, among others, our long-term financial objectives, which include the anticipated effects of our pending acquisition of ANSYS, Inc. (the Ansys Merger); business and market outlook, opportunities, strategies and technological trends, such as artificial intelligence; planned acquisitions and their expected impact, including the Ansys Merger; the potential impact of the uncertain macroeconomic and geopolitical environment on our financial results; the expected impact of U.S. and foreign government trade restrictions and regulatory changes, including export control restrictions and tariffs on our financial results; customer license renewals and the expected realization and timing of our contracted but unsatisfied or partially unsatisfied performance obligations (backlog); planned dispositions and their expected

 

8


impact; customer demand and market expansion for our products and our customers’ products; our ability to successfully compete in the markets we serve; our planned product releases and capabilities; industry growth rates; software trends; planned stock repurchases; our expected tax rate; and the impact and result of pending legal, regulatory, administrative and tax proceedings. These statements involve risks, uncertainties and other factors that could cause our actual results, time frames or achievements to differ materially from those expressed or implied in such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: macroeconomic conditions and geopolitical uncertainty in the global economy; uncertainty in the growth of the semiconductor and electronics industries; the highly competitive industry we operate in; actions by the U.S. or foreign governments, such as the imposition of additional export restrictions or tariffs; consolidation among our customers and our dependence on a relatively small number of large customers; risks and compliance obligations relating to the global nature of our operations; failure to complete the Ansys Merger on the terms described in our filings with the SEC, if at all; failure to obtain required governmental approvals related to the Ansys Merger or the imposition of conditions to such governmental approvals that may have an adverse effect on us; failure to realize the benefits expected from the Ansys Merger; and more. Additional information on potential risks, uncertainties and other factors that could affect Synopsys’ results is included in filings we make with the SEC from time to time, including in the sections entitled “Risk Factors” in our latest Annual Report on Form 10-K and in our latest Quarterly Report on Form 10-Q. The financial information contained in this press release should be read in conjunction with the consolidated financial statements and notes thereto included in Synopsys’ most recent reports on Forms 10-K and 10-Q, each as may be amended from time to time. Synopsys’ financial results for its fourth quarter and fiscal year 2024 are not necessarily indicative of Synopsys’ operating results for any future periods. The information provided herein is as of December 4, 2024. Synopsys undertakes no duty to, and does not intend to, update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.

 

9


SYNOPSYS, INC.

Unaudited Consolidated Statements of Income (1)

(in thousands, except per share amounts)

 

     Three Months Ended     Twelve Months Ended  
     October 31,     October 31,  
     2024     2023     2024     2023  

Revenue:

        

Time-based products

   $ 834,375     $ 780,725     $ 3,224,299     $ 3,016,256  

Upfront products

     520,939       441,494       1,802,222       1,400,125  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total products revenue

     1,355,314       1,222,219       5,026,521       4,416,381  

Maintenance and service

     280,672       245,164       1,100,915       901,633  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     1,635,986       1,467,383       6,127,436       5,318,014  

Cost of revenue:

        

Products

     216,485       197,540       770,238       697,686  

Maintenance and service

     91,707       76,043       367,055       287,876  

Amortization of acquired intangible assets

     66,831       12,598       107,996       45,281  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of revenue

     375,023       286,181       1,245,289       1,030,843  
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross margin

     1,260,963       1,181,202       4,882,147       4,287,171  

Operating expenses:

        

Research and development

     554,818       465,815       2,082,360       1,849,935  

Sales and marketing

     219,225       186,953       859,342       724,934  

General and administrative

     172,032       102,271       568,496       376,677  

Amortization of acquired intangible assets

     4,086       3,346       16,238       9,295  

Restructuring charges

     —        (1,348     —        53,091  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     950,161       757,037       3,526,436       3,013,932  
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     310,802       424,165       1,355,711       1,273,239  

Interest and other income (expense), net

     12,077       (20,400     158,147       32,231  
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     322,879       403,765       1,513,858       1,305,470  

Provision (benefit) for income taxes

     62,084       60,409       99,718       90,188  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income from continuing operations

     260,795       343,356       1,414,140       1,215,282  
  

 

 

   

 

 

   

 

 

   

 

 

 

Income from discontinued operations, net of income taxes

     834,825       3,139       821,670       2,843  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     1,095,620       346,495       2,235,810       1,218,125  

Less: Net income (loss) attributed to non-controlling interest and redeemable non-controlling interest

     (18,486     (2,695     (27,570     (11,763
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributed to Synopsys

   $ 1,114,106     $ 349,190     $ 2,263,380     $ 1,229,888  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributed to Synopsys

        

Continuing operations

   $ 279,281     $ 346,051     $ 1,441,710     $ 1,227,045  

Discontinued operations

     834,825       3,139       821,670       2,843  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

   $  1,114,106     $ 349,190     $  2,263,380     $  1,229,888  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income per share attributed to Synopsys - basic:

        

Continuing operations

   $ 1.81     $ 2.28     $ 9.41     $ 8.06  

Discontinued operations

     5.43       0.02       5.37       0.02  
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic net income per share

   $ 7.24     $ 2.30     $ 14.78     $ 8.08  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income per share attributed to Synopsys - diluted:

        

Continuing operations

   $ 1.79     $ 2.23     $ 9.25     $ 7.91  

Discontinued operations

     5.35       0.03       5.26       0.01  
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted net income per share

   $ 7.14     $ 2.26     $ 14.51     $ 7.92  
  

 

 

   

 

 

   

 

 

   

 

 

 

Shares used in computing per share amounts:

        

Basic

     153,916       151,972       153,138       152,146  
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted

     155,991       154,845       155,944       155,195  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

(1)

Synopsys’ fourth quarter of fiscal year 2024 and 2023 ended on November 2, 2024 and October 28, 2023, respectively. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter.

 

10


SYNOPSYS, INC.

Unaudited Consolidated Balance Sheets (1)

(in thousands, except par value amounts)

 

     October 31, 2024     October 31, 2023  

ASSETS:

    

Current assets:

    

Cash and cash equivalents

   $ 3,896,532     $ 1,433,966  

Short-term investments

     153,869       151,639  
  

 

 

   

 

 

 

Total cash, cash equivalents and short-term investments

     4,050,401       1,585,605  

Accounts receivable, net

     934,470       856,660  

Inventories

     361,849       325,590  

Prepaid and other current assets

     1,122,946       548,115  

Current assets of discontinued operations

     —        114,654  
  

 

 

   

 

 

 

Total current assets

     6,469,666       3,430,624  

Property and equipment, net

     563,006       549,837  

Operating lease right-of-use assets, net

     565,917       559,923  

Goodwill

     3,448,850       3,346,065  

Intangible assets, net

     195,164       239,577  

Deferred income taxes

     1,247,258       853,526  

Other long-term assets

     583,700       444,820  

Long-term assets of discontinued operations

     —        908,759  
  

 

 

   

 

 

 

Total assets

   $  13,073,561     $  10,333,131  
  

 

 

   

 

 

 

LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY:

    

Current liabilities:

    

Accounts payable and accrued liabilities

   $ 1,163,592     $ 1,059,914  

Operating lease liabilities

     94,791       79,832  

Deferred revenue

     1,391,737       1,559,461  

Current liabilities of discontinued operations

     —        286,244  
  

 

 

   

 

 

 

Total current liabilities

     2,650,120       2,985,451  

Long-term operating lease liabilities

     574,065       579,686  

Long-term deferred revenue

     340,831       150,827  

Long-term debt

     15,601       18,078  

Other long-term liabilities

     469,738       381,531  

Long-term liabilities of discontinued operations

     —        33,257  
  

 

 

   

 

 

 

Total liabilities

     4,050,355       4,148,830  
  

 

 

   

 

 

 

Redeemable non-controlling interest

     30,000       31,043  

Stockholders’ equity:

    

Preferred stock, $0.01 par value: 2,000 shares authorized; none outstanding

     —        —   

Common stock, $0.01 par value: 400,000 shares authorized; 154,112 and 152,053 shares outstanding, respectively

     1,541       1,521  

Capital in excess of par value

     1,211,206       1,276,152  

Retained earnings

     8,984,105       6,741,699  

Treasury stock, at cost: 3,148 and 5,207 shares, respectively

     (1,025,770     (1,675,650

Accumulated other comprehensive income (loss)

     (180,380     (196,414
  

 

 

   

 

 

 

Total Synopsys stockholders’ equity

     8,990,702       6,147,308  

Non-controlling interest

     2,504       5,950  
  

 

 

   

 

 

 

Total stockholders’ equity

     8,993,206       6,153,258  
  

 

 

   

 

 

 

Total liabilities, redeemable non-controlling interest and stockholders’ equity

   $  13,073,561     $  10,333,131  
  

 

 

   

 

 

 

 

(1)

Synopsys’ fiscal year 2024 and 2023 ended on November 2, 2024 and October 28, 2023, respectively. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter.

 

11


SYNOPSYS, INC.

Unaudited Consolidated Statements of Cash Flows (1)

(in thousands)

 

     Twelve Months Ended  
     2024     2023  

CASH FLOWS FROM OPERATING ACTIVITIES:

    

Net income

   $  2,235,810     $  1,218,125  

Adjustments to reconcile net income to net cash provided by operating activities:

    

Amortization and depreciation

     295,065       247,120  

Reduction of operating lease right-of-use assets

     97,273       97,705  

Amortization of capitalized costs to obtain revenue contracts

     73,587       82,190  

Stock-based compensation

     692,316       563,292  

Allowance for credit losses

     19,724       19,932  

Gain on sale of strategic investments

     (55,077     —   

Gain on divestitures, net of transaction costs

     (868,830     —   

Amortization of bridge financing costs

     33,677       —   

Deferred income taxes

     (407,649     (211,045

Other

     (1,295     13,295  

Net changes in operating assets and liabilities, net of effects from acquisitions and dispositions:

    

Accounts receivable

     (103,460     (178,432

Inventories

     (51,449     (123,752

Prepaid and other current assets

     (410,432     (106,396

Other long-term assets

     (168,255     (100,618

Accounts payable and accrued liabilities

     187,564       170,496  

Operating lease liabilities

     (96,966     (73,281

Income taxes

     (73,215     198,078  

Deferred revenue

     8,641       (113,435
  

 

 

   

 

 

 

Net cash provided by operating activities

     1,407,029       1,703,274  

CASH FLOWS FROM INVESTING ACTIVITIES:

    

Proceeds from maturities and sales of short-term investments

     138,961       130,435  

Purchases of short-term investments

     (136,821     (131,079

Proceeds from sales of strategic investments

     55,696       8,492  

Purchases of strategic investments

     (1,293     (435

Purchases of property and equipment, net

     (123,161     (189,618

Acquisitions, net of cash acquired

     (156,947     (297,692

Proceeds from business divestiture, net of cash divested

     1,446,578       —   

Capitalization of software development costs

     —        (2,204
  

 

 

   

 

 

 

Net cash provided by (used in) investing activities

     1,223,013       (482,101

CASH FLOWS FROM FINANCING ACTIVITIES:

    

Repayment of debt

     (2,607     (2,603

Payment of bridge financing and term loan costs

     (72,265     —   

Issuances of common stock

     232,212       252,986  

Payments for taxes related to net share settlement of equity awards

     (337,541     (241,408

Purchase of equity forward contract

     —        (45,000

Purchases of treasury stock

     —        (1,160,724

Other

     (1,096     (122
  

 

 

   

 

 

 

Net cash used in financing activities

     (181,297     (1,196,871

Effect of exchange rate changes on cash, cash equivalents and restricted cash

     8,797       (2,979
  

 

 

   

 

 

 

Net change in cash, cash equivalents and restricted cash

     2,457,542       21,323  

Cash, cash equivalents and restricted cash, beginning of year, including cash from discontinued operations

     1,441,187       1,419,864  
  

 

 

   

 

 

 

Cash, cash equivalents and restricted cash, end of period, including cash from discontinued operations

     3,898,729       1,441,187  

Less: Cash, cash equivalents and restricted cash from discontinued operations

     —        4,947  
  

 

 

   

 

 

 

Cash, cash equivalents and restricted cash from continuing operations

   $  3,898,729     $ 1,436,240  
  

 

 

   

 

 

 

 

(1)

Synopsys’ fiscal year 2024 and 2023 ended on November 2, 2024 and October 28, 2023, respectively. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter.

 

12


Synopsys provides segment information, namely revenue, adjusted segment operating income and adjusted segment operating margin, in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 280, Segment Reporting. Synopsys’ chief operating decision maker (“CODM”) is our Chief Executive Officer. In evaluating our business segments, the CODM considers the income and expenses that the CODM believes are directly related to those segments. The CODM does not allocate certain operating expenses managed at a consolidated level to our business segments and, as a result, the reported operating income and operating margin do not include these unallocated expenses as shown in the table below. These unallocated expenses are presented in the table below to provide a reconciliation of the total adjusted operating income from segments to our consolidated operating income from continuing operations:

SYNOPSYS, INC.

Business Segment Reporting (1)(2)(5)

(in millions)

 

     Three Months Ended
October 31, 2024
    Three Months Ended
October 31, 2023
    Twelve Months Ended
October 31, 2024
    Twelve Months Ended
October 31, 2023
 

Revenue by segment

        

- Design Automation

   $  1,118.2     $  953.7     $  4,221.1     $  3,775.3  

% of Total

     68.3     65.0     68.9     71.0

- Design IP

   $ 517.8     $ 513.7     $ 1,906.3     $ 1,542.7  

% of Total

     31.7     35.0     31.1     29.0

Adjusted operating income by segment

        

- Design Automation

   $ 413.3     $ 311.1     $ 1,631.9     $ 1,413.9  

- Design IP

   $ 189.9     $ 236.4     $ 730.2     $ 514.1  

Adjusted operating margin by segment

        

- Design Automation

     37.0     32.6     38.7     37.5

- Design IP

     36.7     46.0     38.3     33.3

 

13


Total Adjusted Segment Operating Income Reconciliation (1)(2)(5)

(in millions)

 

     Three Months Ended
October 31, 2024
     Three Months Ended
October 31, 2023
     Twelve Months Ended
October 31, 2024
     Twelve Months Ended
October 31, 2023
 

GAAP total operating income – as reported

   $ 310.8      $ 424.2      $ 1,355.7      $ 1,273.2  

Other expenses managed at consolidated level

           

-Amortization of acquired intangible assets (3)

     70.9        15.9        124.2        54.6  

-Stock-based compensation (3)

     165.4        128.6        657.9        513.1  

-Non-qualified deferred compensation plan

     9.2        (23.9      85.4        20.2  

-Acquisition/divestiture related items (4)

     47.0        4.0        138.7        13.8  

-Restructuring charges

     —         (1.3      —         53.1  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total adjusted segment operating income

   $  603.2      $  547.5      $  2,362.1      $  1,928.0  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1)

Synopsys manages the business on a long-term, annual basis, and considers quarterly fluctuations of revenue and profitability as normal elements of our business. Amounts may not foot due to rounding.

 

(2)

Synopsys’ fourth quarter of fiscal year 2024 and 2023 ended on November 2, 2024 and October 28, 2023, respectively. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter.

 

(3)

The adjustment includes non-GAAP expenses attributable to non-controlling interest and redeemable non-controlling interest.

 

(4)

The adjustment excludes the amortization of bridge financing costs entered into in connection with the pending acquisition of Ansys, that was recorded in interest and other income (expense), net, in our unaudited condensed consolidated statements of income.

 

(5)

Presented on a continuing operations basis.

GAAP to Non-GAAP Reconciliation

Synopsys continues to provide all information required in accordance with GAAP but acknowledges evaluating its ongoing operating results may not be as useful if an investor is limited to reviewing only GAAP financial measures. Accordingly, Synopsys presents non-GAAP financial measures in reporting its financial results to provide investors with an additional tool to evaluate Synopsys’ operating results in a manner that focuses on what Synopsys believes to be its core business operations and what Synopsys uses to evaluate its business operations and for internal budgeting and resource allocation purposes. This press release includes non-GAAP earnings per diluted share, non-GAAP net income and non-GAAP tax rate for the periods presented. It also includes future estimates for non-GAAP expenses, non-GAAP interest and other income (expense), non-GAAP tax rate, non-GAAP earnings per diluted share and free cash flow. These non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.

 

14


When possible, Synopsys provides a reconciliation of non-GAAP financial measures to their most closely applicable GAAP financial measures. Synopsys is unable to provide a full reconciliation of certain first quarter and full fiscal year 2025 non-GAAP financial targets to the corresponding GAAP financial measures on a forward-looking basis because Synopsys believes that it would not be possible for it to have the required information necessary to quantitatively reconcile such measures with sufficient precision without unreasonable efforts due to, among other things, the potential variability and limited predictability of the excluded adjustment items necessary for a full reconciliation such as certain acquisition/divestiture related items, restructuring charges, tax deduction variability, changes in the fair value of non-qualified deferred compensation plan, and gains (losses) on the sale of strategic investments. For the same reasons, Synopsys is unable to address the probable significance of the unavailable information.

Synopsys’ management does not itself, nor does it suggest that investors should, consider such non-GAAP financial measures in isolation from, as superior to, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are meant to supplement, and be viewed in conjunction with, the corresponding GAAP financial measures. Synopsys’ management believes presentation of non-GAAP financial measures, when shown in conjunction with the corresponding GAAP financial measures, provides useful information to investors allowing them to view financial and business trends relating to our financial condition and results of operations through the eyes of management. Synopsys’ management evaluates and makes decisions about our business operations using both GAAP financial measures and non-GAAP financial measures to help facilitate internal comparisons to Synopsys’ historical operating results and forecasted targets, planning and forecasting in subsequent periods and comparisons to competitors’ operating results.

The following are descriptions of the adjustments made to reconcile non-GAAP financial measures (other than free cash flow, which is defined in the footnote to the Financial Targets table above) to the most directly comparable GAAP financial measures:

(i) Amortization of acquired intangible assets. We incur expenses from amortization of acquired intangible assets, which may include impairment charges from write-downs of acquired intangible assets. Acquired intangible assets include, among other things, core/developed technology, customer relationships, contract rights, trademarks and trade names, and other intangibles related to acquisitions. We amortize the intangible assets over their estimated useful lives. We do not enter into acquisitions on a predictable cycle. The amount of an acquisition’s purchase price allocated to intangible assets and their estimated useful lives can vary significantly and are unique to each acquisition. From time to time, we incur impairment charges

 

15


due to write-downs of acquired intangible assets. We believe that the presentation of non-GAAP financial measures that adjust for the amortization of intangible assets, including impairment charges, provides investors and others with a consistent basis for comparison across accounting periods. We also exclude this item because such expenses are non-cash in nature and we believe the non-GAAP financial measures excluding this item provide meaningful supplemental information regarding our core operational performance and liquidity, and ability to invest in research and development and fund future acquisitions and capital expenditures.

(ii) Stock-based compensation. Stock-based compensation expenses consist primarily of expenses related to restricted stock units, stock options, employee stock purchase rights and other stock awards, including such expenses associated with acquisitions. We exclude stock-based compensation expense from our non-GAAP financial measures primarily because it is not an expense that typically requires or will require cash settlement by us. Further, the expense for the fair value of the stock-based instruments we utilize may bear little resemblance to the actual value realized upon the vesting or future exercise of the related stock-based awards and, therefore, is not used by management to assess the core profitability of our business operations.

(iii) Acquisition/divestiture related items. In connection with certain of our business combinations and/or divestitures, we incur significant expenses that we would not have otherwise incurred as part of our business operations. These expenses include, among other things, compensation expenses, professional fees and other direct expenses, concurrent restructuring activities and divestiture activities, including employee severance and other exit costs, bridge financing costs, costs related to integration activities, changes to the fair value of contingent consideration related to the acquired company, and amortization of the fair value difference of below-market value assets arising from arrangements entered into or acquired in conjunction with an acquisition. We also recognize the gains and losses from the mark-up of equity or cost method investments to fair value upon obtaining control through acquisition. We exclude these items because they are related to acquisitions and have no direct correlation to the core operation of our business. Further, because we do not acquire businesses on a predictable cycle and the terms of each transaction can vary significantly and are unique to each transaction, we believe it is useful to exclude such expenses when looking for a consistent basis for comparison across accounting periods.

 

16


(iv) Restructuring charges. We initiate restructuring activities to align our costs to our operating plans and business strategies based on then-current economic conditions, and such activities have a specific and defined term. Restructuring costs generally include severance and other termination benefits related to voluntary retirement programs, involuntary headcount reductions and facilities closures. Such restructuring costs include elimination of operational redundancy, permanent reductions in workforce and facilities closures and, therefore, are not considered by us to be a part of the core operation of our business and are not used by management when assessing the core profitability and performance of our business operations.

(v) Gains (losses) on the sale of strategic investments. We exclude gains and losses on the sale of equity investments in privately held companies because we do not believe they are reflective of our core business and operating results.

(vi) Deferred compensation. We exclude changes in the fair value of our non-qualified deferred compensation plan because we do not use these to assess the core profitability of our business operations.

(vii) Income tax effect of non-GAAP pre-tax adjustments. Excluding the income tax effect of non-GAAP pre-tax adjustments from the provision for income taxes assists investors in understanding the tax provision associated with those adjustments and the effect on net income. We utilize an annual non-GAAP tax rate in calculating non-GAAP financial measures to provide better consistency across interim reporting periods by eliminating the effects of certain non-recurring and other period-specific items, which can vary in size and frequency and do not necessarily reflect our normal operations, and to more closely align our tax rate with our expected geographic earnings mix. This annual non-GAAP tax rate is based on an evaluation of our historical and projected mix of U.S. and international profit before tax, taking into account the impact of non-GAAP adjustments, U.S. tax law changes, as well as other factors such as our current tax structure, existing tax positions and expected recurring tax incentives. Based on these considerations, we have elected to adopt a non-GAAP tax rate of 16% for fiscal year 2025.

 

17

v3.24.3
Document and Entity Information
Dec. 04, 2024
Cover [Abstract]  
Entity Registrant Name SYNOPSYS INC
Amendment Flag false
Entity Central Index Key 0000883241
Document Type 8-K
Document Period End Date Dec. 04, 2024
Entity Incorporation State Country Code DE
Entity File Number 000-19807
Entity Tax Identification Number 56-1546236
Entity Address, Address Line One 675 Almanor Ave.
Entity Address, City or Town Sunnyvale
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94085
City Area Code (650)
Local Phone Number 584-5000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock (par value of $0.01 per share)
Trading Symbol SNPS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

Synopsys (NASDAQ:SNPS)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Synopsys Charts.
Synopsys (NASDAQ:SNPS)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Synopsys Charts.